[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ewings-sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ewings-sarcoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":44},"100319721","assessment-of-healing-and-function-after-reconstruction-surgery-for-bone-sarcomas-100319721",false,"NCT03442465","Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas","Assessment of Healing and Function After Surgical Reconstruction for Neoplasms Involving Bone","Inclusion Criteria:\n\n* All patients undergoing reconstructive surgery for neoplasms involving bone on the orthopaedic surgery service at MSK\n* Current or prior history of primary neoplasms involving osseous structures, including all subtypes\n* Confirmation of diagnosis that has been performed by the MSK's Department of Pathology via direct review of tissue\u002Fslides\n* Patients must read and understand English\n* Age \\>\u002F=4\n* Patients must read and understand English\n\nExclusion Criteria:\n\n* Patients that weight \\\u003C17 kilograms","ALL","4 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to look at the amount of function that returns in participants that have reconstruction with bone graft or artificial device and in participants who have tumor surgery plus regenerative osseous surgery.\n\nThe study will look at the level of function for a period of 3 years after the surgery. Another purpose of this study is to look at how well the bone heals in participants undergoing regenerative surgery",[24,25,26,27,28,29],"Bone Sarcoma","Osteosarcoma","Chondrosarcoma","Ewing's Sarcoma","Osseous Sarcoma","Bone Neoplasm",[31,32],"18-014","Memorial Sloan Kettering Cancer Center","RECRUITING","2026-04-16",{"date":36,"type":37},"2026-04-17","ACTUAL",{"date":39,"type":37},"2018-02-14",{"date":41,"type":20},"2027-02-14",{"name":32,"class":43},"OTHER",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100596652","early-phase-1-single-arm-romiplostim-to-prevent-cit-100596652","NCT07048249","Single Arm Romiplostim to Prevent CIT","Single Arm Evaluation of Romiplostim to Prevent Chemotherapy Induced Thrombocytopenia in Patients With Ewing Sarcoma","Inclusion Criteria:\n\n* Age: Patients must be \\>1 year old at the time of study consent.\n* Diagnosis: Patients with a new diagnosis of Ewing sarcoma treated with interval-compressed chemotherapy as per AEWS0031, AEWS1221, or AEWS1031.\n* Informed Consent: All patients and\u002For their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.\n\nExclusion Criteria:\n\n* Marrow disease: Patients with metastatic Ewing sarcoma to the bone marrow are not eligible. Marrow staging is not required for this study but should be performed if clinically indicated.\n* Concomitant therapy, cancer directed: Patients receiving whole lung radiation, \\>50% of pelvic irradiation, other substantial bone marrow radiation (i.e. ≥ 50% of vertebral marrow space), or patients undergoing pneumonectomy as a component of local control before cycle 14, are not eligible. These therapies are not an exclusion if instituted during or after cycle 14.\n* Concomitant therapy, non-cancer directed:\n\n  * Patients requiring hematopoietic stem cell rescue are not eligible.\n  * Previous use of romiplostim, eltrombopag or any other platelet-producing agent is not allowed.\n  * Previous therapy for immune thrombocytopenia and related conditions, including rituximab, mycophenolic acid, protracted systemic steroids, and\u002For IVIG, is prohibited.\n  * Treatment with erythropoietin-stimulating agents is prohibited.\n  * Patients receiving another investigational drug are not eligible.\n  * Patients who are receiving prophylactic dosing of heparin (i.e. enoxaparin) or oral anticoagulants (i.e. rivaroxaban) for thrombosis prevention may be considered for enrollment but will be excluded from secondary aim 'a' analysis (efficacy measured as the median platelet count and transfusion dependency) given shift in transfusion thresholds.\n* Concurrent Illnesses: Patients with a history of or current diagnosis of bone marrow failure, hematologic malignancy, pro-thrombotic condition, or platelet disorder (including immune or heparin induced thrombocytopenia) are not eligible.\n* Patients who in the opinion of the investigator may not be able to comply with the study (including safety monitoring requirements of the study) are not eligible.","1 Year",{"count":54,"type":20},26,"INTERVENTIONAL",[57],"EARLY_PHASE1","The goal of this clinical trial is to to assess the efficacy of romiplostim as a supportive care measure in patients with a new diagnosis of Ewing sarcoma receiving interval-compressed chemotherapy. The main questions it aims to answer are:\n\n1. To demonstrate the efficacy of romiplostim in patients with newly diagnosed Ewing sarcoma, measured specifically as the rate of CIT, defined as a failure to achieve platelet recovery (≥ 75,000\u002FµL post nadir, without transfusion, or a platelet count sufficient to resume chemotherapy per provider and institutional standard) within 7 days of planned chemotherapy cycle start, measured during the continuation phase (cycle 7 to end of cycle 13 or 16, per AEWS0031\u002FAEWS1221, or AEWS1031 respectively) of interval-compressed chemotherapy (every 2 week vincristine\u002Fcyclophosphamide +\u002F- doxorubicin and ifosfamide\u002Fetoposide chemotherapy) as compared to published institutional historical control rate.\n2. To determine the safety of incorporation of romiplostim supportive care when given concurrently with Ewing sarcoma therapy.\n3. To determine the feasibility of incorporation of romiplostim supportive care into upfront Ewing sarcoma regimens.",[60,61],"Ewings Sarcoma","Chemotherapy Induced Thrombocytopenia",[63,64,65,66,67],"romiplostim","ewing sarcoma","chemotherapy induced thrombocytopenia","CIT","NPLATE","2026-03-16",{"date":70,"type":37},"2026-03-18",{"date":72,"type":37},"2024-01-26",{"date":74,"type":20},"2028-01-01",{"name":76,"class":43},"Children's Hospital Medical Center, Cincinnati",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":55,"phases":88,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100600039","phase-2-a-randomized-controlled-study-comparing-the-safety-and-efficacy-of-irinotecan-hydrochloride-liposome-injection-combined-with-temozolomide-and-vincristine-naliri-vt-versus-irinotecan-combined-with-temozolomide-and-vincristine-vit-in-patients-with-advanced-ewings-sarcoma-100600039","NCT07092306","A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma","Inclusion Criteria:\n\n* 1\\. The subject or their legal representative must sign the written informed consent before enrollment.\n\n  2\\. Age ≥ 8 years and ≤ 40 years, both male and female are eligible. 3. Pathologically confirmed Ewing's sarcoma, and detailed pathological reports must be provided. Pathology must be confirmed by fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS) to show the presence of Ewing's sarcoma-specific FET family (including EWSR1 or FUS) gene breaks. This study does not impose special restrictions on fusion partner genes, but clear FET-non ETS fusions (such as EWSR1-WT1, EWSR1-NFATC2, EWSR1-PATZ1, etc.) do not meet the enrollment criteria.\n\n  4\\. At least one measurable target lesion as judged by RECIST 1.1 criteria. 5. Failure of first-line standard treatment. First-line standard treatment includes the following drugs: doxorubicin, cyclophosphamide and\u002For ifosfamide. Treatment failure is defined as disease progression during adjuvant chemotherapy or within 6 months after chemotherapy. For disease progression more than 6 months after chemotherapy, the consent of the subject or their legal representative is required.\n\n  6\\. ECOG score: 0-1. 7. Expected survival ≥ 3 months. 8. Recovery from previous treatment: According to NCI-CTCAE 5.0, all side effects (except alopecia) must have subsided to grade 1 or below.\n\n  9\\. Normal major organ function, meeting the following criteria:\n\n  1\\) Blood routine examination must meet the following criteria (no blood transfusion, no use of hematopoietic factors, and no drug correction within 14 days):\n  1. ANC ≥ 1.5×109\u002FL;\n  2. HB ≥ 90 g\u002FL;\n  3. PLT ≥ 100×109\u002FL; 2) Biochemical examination must meet the following criteria:\n\n  \u003C!-- -->\n\n  1. TBIL ≤ 1.5 ULN;\n  2. ALT, AST ≤ 2.5 ULN (if liver function abnormalities are due to liver metastasis, then ≤ 5 ULN);\n  3. Serum creatinine sCr ≤ 1.5 ULN, endogenous creatinine clearance rate ≥ 50 ml\u002Fmin (Cockcroft-Gault formula); 3) Coagulation function must meet the following criteria: INR ≤ 1.5 and APTT ≤ 1.5 ULN.\n\n     10\\. Women of childbearing age must have taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within one week before enrollment, with a negative result, and be willing to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug. For men, they must agree to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug or have undergone surgical sterilization.\n\n     Exclusion Criteria:\n* 1\\. Known hypersensitivity, anaphylaxis or intolerance to irinotecan liposome, temozolomide and vincristine or their excipients; 2. Within 2 weeks after the last systemic cytotoxic drug treatment, radiotherapy, targeted therapy or any anti-tumor drug treatment except immunotherapy; 3. Patients who have received irinotecan treatment before; 4. Other malignant tumors within the past 5 years; 5. Known symptomatic central nervous system metastases; 6. Known symptomatic brain metastases, spinal cord compression, carcinomatous meningitis, or unstable brain or leptomeningeal disease found on CT or MRI at screening; 7. Symptomatic serous cavity effusion (including pleural effusion, ascites, pericardial effusion) requiring surgical intervention; 8. Uncontrolled concomitant diseases, including but not limited to: poorly controlled hypertension, heart failure, diabetes, persistent active infection, poorly controlled active peptic ulcer, or mental disorders or social conditions that may affect the subject's compliance with the study; 9. Abnormal coagulation function (INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4s or APTT \\> 1.5 ULN), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; 10. Treatment with anticoagulants or vitamin K antagonists such as warfarin, heparin or similar drugs; Note: Under the condition of INR ≤ 1.5, low-dose heparin (adult daily dose of 6,000 - 12,000 U), low-dose aspirin (daily dose ≤ 100 mg), or rivaroxaban (daily dose ≤ 10 mg) for preventive purposes is allowed; 12. History of drug abuse of psychotropic drugs and unable to quit or with mental disorders; 13. Known hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.); 14. Open wounds, fractures, or poorly healing wounds; 15. Major surgery within 2 weeks; 16. Confirmed inflammatory bowel disease, intestinal obstruction or chronic diarrhea; 17. Cavity organ fistula or perforation within 6 months; 18. Active hepatitis B or C virus infection or active infection requiring antimicrobial treatment (such as the use of antibacterial drugs, antiviral drugs, antifungal drugs); 19. Participation in other interventional anti-tumor clinical trials within 4 weeks; 20. Patients who have used strong CYP3A4 inducers or strong CYP3A4 inhibitors or strong UGT1A1 inhibitors within 3 weeks before the first dose; 21. Lactation; 22. Any condition that the investigator deems may harm the patient or prevent the patient from meeting or fulfilling the study requirements.","8 Years","40 Years",{"count":87,"type":20},74,[89],"PHASE2","This study is a randomized, controlled, multicenter, prospective clinical trial with a planned enrollment of 74 patients, who will be randomly assigned in a 2:1 ratio. After enrollment, patients will receive either irinotecan liposomal injection combined with temozolomide and vincristine or irinotecan injection combined with temozolomide and vincristine. The aim is to evaluate the efficacy, safety, and impact on quality of life of the irinotecan liposomal combination regimen compared to the irinotecan injection combined with temozolomide and vincristine in the treatment of advanced Ewing's sarcoma.",[27],[93,94,95,96,27],"Irinotecan Hydrochloride Liposome Injection","NALIRI-VT","Temozolomide","Vincristine","NOT_YET_RECRUITING","2025-07-22",{"date":100,"type":37},"2025-07-29",{"date":102,"type":20},"2025-08-10",{"date":104,"type":20},"2027-05-01",{"name":106,"class":43},"Tang Xiaodong"]